Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pleneva in RRMS
NCT01037907Phase 2Terminated
- Sponsor
- Boston Scientific Corporation
- Start
- Nov 2009
- Primary completion
- Dec 2011
- Modality
- Solid Lipid Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of BGC20-0134 in multiple sclerosis (MS), sponsored by Boston Scientific Corporation. Started Nov 2009; status: terminated.
02
Drugs
BGC20-0134
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01037907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037907.